In this study, we report the comparative result of long-term clinical prognoses for patients with no-option critical limb ischemia (CLI) caused by arteriosclerosis obliterans, who are implanted with autologous bone marrow mononuclear cells (BMMNC; n ¼ 74) or G-CSF-mobilized (M)-PBMNC (n ¼ 111), as no information is available on how the two treatments compare in terms of long-term prognosis, such as survival or amputation. We performed pooled analysis using data from two previous cohort studies. All patients had disease of Fontaine classification III or IV. The endpoints were OS and amputation-free survival (AFS). After adjustment for history of dialysis and Fontaine classification, there was no significant difference between the two treatments with respect to OS (hazard ratio (HR) ¼ 1.49; 95% confidence interval (CI) ¼ 0.74-3.03, P ¼ 0.26) or AFS (HR ¼ 0.96; 95% CI ¼ 0.61-1.51, P ¼ 0.87). The negative prognostic factors affecting OS or AFS were the small number of CD34-positive cells collected, history of dialysis, Fontaine classification, male sex and older age. These results suggest that there was no significant difference in long-term prognosis between patients treated with BMMNC and those treated with M-PBMNC. The number of CD34-positive cells collected was an important prognostic factor for amputation and death.
Introduction
Patients with critical limb ischemia (CLI), who suffer from rest pain, non-healing ischemic ulcers or necrosis (that is, Fontaine III or IV disease) rarely respond to standard therapies, and are at high risk of limb loss and serious, possibly fatal, vascular events. 1 Arteriosclerosis obliterans (ASO) is a common cause of CLI, and patients with this condition have a particularly poor prognosis. In the past decade, many cell therapies for CLI have been developed. The types of therapeutic cells used till date have been bone marrow mononuclear cells (BMMNC), [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] PBMNC, 2, 12, 13 G-CSF-mobilized (M)-PBMNC, [14] [15] [16] [17] [18] CD34-antigen-positive mononuclear cells 19, 20 and CD133-antigen positive cells. 21 Although BMMNC or M-PBMNC intramuscular implantation has been used most often, both therapies have some risk: to collect about 500 mL of BMMNC, general anesthesia of about 4 h duration is necessary, and to collect PBMNC, about 3 h of apheresis with G-CSF treatment is required. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [14] [15] [16] [17] [18] In a first cell-therapy trial, results of which were published in 2002, 22 ASO patients (44 limbs) were implanted with either BMMNC or PBMNC.
2 At 6 months after implantation, both therapies yielded improvements in terms of rest pain, ABI and transcutaneous oxygen pressure, but the clinical outcomes for BMMNC were significantly better than those for PBMNC. In a randomized trial, Arai et al. 10 compared the outcomes for ASO patients treated with BMMNC, G-CSF or conventional therapy. These authors observed that the BMMNC and G-CSF groups had significantly better outcomes than the control group with respect to ABI and transcutaneous oxygen pressure, and that there was no significant difference between the BMMNC and G-CSF groups with respect to ABI and transcutaneous oxygen pressure. In another randomized controlled trial, Huang et al. 17 compared BMMNC and M-PBMNC for the treatment of ASO, and showed that both therapies yielded a benefit at 3 months after implantation, and that M-PBMNC produced significantly greater improvements than BMMNC with respect to rest pain, skin temperature and ABI. Recently, the result of a meta-analysis of 37 trials was reported. In those trials, patients with CLI-implanted BMMNC or M-PBMNC were followed for a median of 6 months (interquartile range: [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] . 22 This meta-analysis indicated that intramuscular cell therapies were effective in improving the clinical endpoints of ABI, transcutaneous oxygen pressure, pain-free walking distance and pain.
However, despite the facts that the patients with CLI are at high risk of limb loss or death, and saving the limb as well as survival is the principal aim of cell therapies, these trials did not evaluate the long-term hard endpoints, such as amputation and death. Only two studies of Matoba et al. 11 and Horie et al. 18 evaluated long-term prognosis of over 200 patients implanted with BMMNC or M-PBMNC, and followed up over 2 year (median). However, these two studies do not add to our understanding of the relative efficacies of the two therapies because these studies were uncontrolled, so the comparative merits and shortcomings of the two cell therapies remain unknown. Moreover, in these long-term studies, 11, 18 serious adverse events (SAEs), including heart failure and malignant tumors occurred, although the causal association between SAEs and cell therapies was unclear. For patients with CLI, who are in a position to select a therapy, having access to long-term prognostic information on the choice of BMMNC or M-PBMNC treatment would be extremely useful. Although a prospective randomized controlled trial would be the best option for comparing BMMNC and M-PBMNC, such a trial would require long-term follow-up and would be expensive. Therefore, in this study we chose to use pooled analysis of long-term follow-up data instead.
In this study, for patients with ASO-induced CLI, who were treated with either M-PBMNC or BMMNC, we compared long-term prognoses and identified prognostic factors for clinical outcomes. Data were obtained from the cohort studies of Matoba et al. 11 and Horie et al.
18

Materials and methods
Data sources and patients
We collected data on individual patients from two previously published cohort studies, Matoba et al. 11 and Horie et al. 18 The former patient cohort consisted of 115 patients who were implanted with BMMNC between In the studies by Matoba et al. 11 and Horie et al., 18 patients with thromboangiitis obliterans, diabetic gangrene, connective tissue disease or both ASO and Fontaine II disease had a better prognosis than patients with both ASO and Fontaine III or IV disease, and had no or few deaths or amputation events. Therefore, the following patients were excluded to achieve comparability between the two cohorts of homogenous populations: for the BMMNC treatment group, patients who had thromboangiitis obliterans (41 patients); and for the M-PBMNC treatment group, those who had thromboangiitis obliterans (11 patients), diabetic gangrene (4 patients), connective tissue disease (7 patients), and Fontaine II or unclassified disease (29 patients). The diabetic gangrene patients were placed in a different group from patients with ASO because their toe blood pressure was within the normal range and their underlying pathology was neuropathy rather than angiopathy. Consequently, a total of 185 patients were included in this study, including 74 patients treated with BMMNC and 111 patients treated with M-PBMNC, all of whom had Fontaine III or IV ASO.
Cell therapy procedures
The procedures used for the BMMNC and M-PBMNC treatment trials have been described in detail previously. 2, 11, 14, 18 Briefly, for BMMNC treatment, marrow cells (about 500 mL) were aspirated from the ilium with the patient under general anesthesia, then placed into plastic bags containing heparin. Mononuclear cells were sorted to 95% purity and concentrated to a final volume of about 40 mL. Approximately 3 h after marrow aspiration, about 0.3 mL of the cell solution was injected intramuscularly into each of 100-130 sites in the gastrocnemius of the ischemic limb.
For M-PBMNC treatment, bone marrow stem cells were mobilized to the peripheral blood by administration of G-CSF. For this purpose, each patient was given 5 or 10 mg/kg/day G-CSF subcutaneously for a total of 4 days. When the white blood cell count reached 20 000-40 000/ mm 3 , approximately 60 mL of a cell suspension comprising mononuclear cells was collected from the peripheral blood using an apheresis technique. Within 1 h, approximately 0.5 mL aliquots of the unpurified collected mononuclear cell suspension were injected into each of 15-160 sites in the gastrocnemius or plantar muscle of the ischemic limb. Some patients underwent two implantation sessions.
The number of CD34-positive (CD34 þ ) cells in the mononuclear cell suspension was calculated using flow cytometry according to the methods of the International Society for Cellular Therapy.
Measurement
In both studies, the following variables were ascertained for each patient at baseline: age, sex, Fontaine classification, history of dialysis, history of smoking, comorbidities/ medical history (hypertension, hyperlipidemia, diabetes mellitus, ischemic heart disease and cerebrovascular disorder) and history of bypass surgery. Furthermore, the number of endothelial progenitor cells (that is, CD34 
Endpoints
Endpoints were OS, defined as the time from the first day of treatment to death, and amputation free survival (AFS), defined as the time from the first day of treatment to the day of lower limb amputation or death. In this study, lower limb amputation refers to major (over ankle) amputation.
Statistical analyses
Comparison of treatments. To compare the BMMNC and M-PBMNC treatment groups, we used time-to-event methods. As these studies were not randomized, it was necessary to adjust for confounding factors to obtain unbiased measures of treatment effect. Therefore, to adjust for confounding factors, we first identified influential confounding factors through an assessment of variables that differed greatly between the two treatment groups, using Fisher's exact test and by change-in-estimate methods with a criterion of a 20% change in the hazard ratio (HR) of interest. 23 Candidate confounding factors were age, sex, Fontaine classification, history of smoking, dialysis, hypertension, hyperlipidemia, diabetes mellitus, ischemic heart disease, cerebrovascular disorder, bypass surgery and the number of CD34 þ cells collected (high/low). To obtain adjusted HR values with 95% confidence intervals for treatment comparison, we used Cox's regression analysis.
Prognostic factor analysis. To identify prognostic factors for OS and AFS, we used Cox's proportional hazards model with backward variable selection, with a criterion of Po0.10. Candidate variables included in the multivariate analysis were age, sex, Fontaine classification, history of smoking, dialysis, hypertension, hyperlipidemia, diabetes mellitus, ischemic heart disease, cerebrovascular disorder, bypass surgery, the number of CD34 þ cells collected (high/ low) and cell-therapy type. All statistical analyses were performed using SAS version 9.1 (SAS Institute, Cary, NC, USA).
Results
Patient characteristics
There were considerable differences in the baseline clinical characteristics of patients in the M-PBMNC and BMMNC groups (Table 1 ). In particular, there were more patients on dialysis in the M-PBMNC group than in the BMMNC group. The median follow-up times for surviving patients were 34.9 months (range: 0.8-69 months) for the BMMNC study, and 21.1 months (range: 0.4-62.2 months) for the M-PBMNC study. Out of the 74 patients in the BMMNC group, 11 died, 24 underwent above ankle amputation and 31 died and/or underwent above ankle amputation. Out of the 111 patients in the M-PBMNC group, 42 died, 39 underwent above ankle amputation and 61 died and/or underwent above ankle amputation.
Comparison of cell therapies
When OS and AFS were compared for the BMMNC and M-PBMNC groups in a crude comparison (unadjusted for confounders), the 2-year OS rate after implantation was 80% in the BMMNC group and 64% in the M-PBMNC group, and the 2-year AFS rate after implantation was 53% in the BMMNC group and 43% in the M-PBMNC group. However, a change-in-estimate procedure revealed that adjustment for dialysis and Fontaine classification was necessary. Table 2 shows the HR and P-values for the two endpoints after adjustment for history of dialysis and Fontaine classification. The M-PBMNC group tended to have poorer OS than the BMMNC group, although the Figure 1 . The 2-year OS rates after BMMNC and M-PBMNC implantation were 89 and 86%, respectively, among non-dialysis patients, and 57% for both treatments among dialysis patients. The 2-year AFS rates were 66 and 73% among non-dialysis patients, and 29 and 34% among dialysis patients.
Prognostic factors
Variable selection analysis indicated that the number of CD34 þ cells collected, dialysis and sex independently affected both OS and AFS. Other independent prognostic factors identified by variable selection were age for OS, and Fontaine classification for AFS (Table 3) . Moreover, males had an approximately two-fold higher risk than females for both endpoints; the risk for dialysis patients was 4.4 or 2.0-fold higher than for non-dialysis patients in terms of OS and AFS, respectively; the risk for Fontaine IV was 3.5-fold higher than for Fontaine III Table 2 Comparison between cell therapies with respect to overall survival and amputation-free survival after adjusting for dialysis and Fontaine classification Long-term outcomes of cell therapies for ASO R Onodera et al disease in terms of AFS; and older patients had a higher risk in terms of OS.
Discussion
This is, to the best of our knowledge, the first study in which the long-term clinical prognoses of patients with ASO-induced CLI treated with BMMNC and M-PBMNC implantation have been compared. In this study, OS and AFS were selected as endpoints, especially; AFS is the main criterion, because death and amputation of a lower limb are the most clinically important potential outcomes for patients with ASO-induced no-option CLI. This study yielded two major findings. First, there were no clear differences in terms of OS or AFS among CLI patients with ASO, who were treated with BMMNC and M-PBMNC (Table 2) . A history of dialysis has been identified as an unfavorable prognostic factor for treatment outcome in these patients; however, no pooled analysis for prognostic factors has been previously reported. In this study, we identified a history of dialysis as a strong independent prognostic factor of not only AFS but also OS. As shown in Figure 1 , the Kaplan-Meier curves for AFS and OS were clearly different for dialysis and non-dialysis patients; however, no difference was observed between patients receiving BMMNC and M-PBMNC. Given the absence of a control group in this study, our findings shed no light on the long-term efficacy of either of the two cell therapies, but our data show that their long-term prognosis are likely to be similar. To date, there have been several studies that have evaluated the long-term prognoses of CLI patients treated with conventional therapy. Shigematsu et al. 24 reported a 1-year OS of 81.5% for CLI patients with ASO, and Koch et al. 25 and Biancari et al. 26 reported corresponding figures for CLI patients on dialysis of 74 and 51%, respectively. In our study, for all ASO patients, the 1-year OS rate was 76% for the M-PBMNC group and 93% for the BMMNC group. Corresponding figures for the non-dialysis patients were 95% for the M-PBMNC group and 93% for the BMMNC group, and for the dialysis patients the values were 70% for the M-PBMNC group and 94% for the BMMNC group. Therefore, it seems that the OS for patients treated with cell therapies is not inferior to that of patients treated with conventional therapies. In terms of 1-year AFS, Biancari et al. 26 reported a value of 46% for dialysis patients who underwent infrainguinal bypass grafting or endovascular treatment, other than that the patients expected poor results. In the study by Schanzer et al., 27 1-year AFS values for patients who underwent vein bypass surgery were 49.3% for dialysis patients and 79.5% for non-dialysis patients. In our study, corresponding values for the dialysis patients were 46% for the M-PBMNC group and 52% for the BMMNC group, so based on these data AFS for cell therapies is almost equal to that of conventional therapy. However, in our group 477% of patients did not undergo vein bypass surgery, and our patients almost certainly had more severe disease than those in the studies of Biancari et al. 26 and Schanzer et al. 27 Therefore, the results of these studies cannot be directly compared. In their meta-analysis, Table 3 Prognostic factors affecting overall survival and amputation-free survival, identified using Cox's regression analysis with backward variable selection Long-term outcomes of cell therapies for ASO R Onodera et al Fadini et al. 22 reported that the M-PBMNC group had a significantly better short-term outcome than the BMMNC group in terms of pain, but that the reverse was true for ulcer healing. However, we observed no clear differences in terms of either OS or AFS between the BMMNC group and the M-PBMNC group. Therefore, we surmise that differences in short-term prognosis (that is, at about 6 months) do not greatly influence long-term prognosis. Given that data on short-term efficacy in terms of rest pain, skin temperature, ABI and so on have been reported elsewhere, 17, 22 in the future, the choice of cell therapy will be made according to factors such as time to benefit, the likelihood of avoiding pain and reducing ulcer size, the likely impact of invasive procedures during cell collection, the risk of adverse events and cost. Currently, cell collection and implantation of BMMNC and M-PBMNC are performed on an inpatient basis, but in the future, M-PBMNC therapy will be undertaken as an outpatient procedure. Reducing the burden on patients in this way will become a consideration when making decisions about therapeutic approach.
The second important finding was that the number of CD34 þ cells collected was a prognostic factor for both OS and AFS. The high CD34
þ harvest group had a better prognosis than the low CD34 þ harvest group with respect to both endpoints (Figure 2) . Similarly, when the data were analyzed using the number of CD34 þ cells collected as a continuous variable, the number of CD34 þ cells was a prognostic factor for both OS and AFS as follows: HR for OS ¼ 0.90 (95% CI ¼ 0.82-0.99, P ¼ 0.03) for pooled patients; HR for AFS ¼ 0.94 (95% CI ¼ 0.89-1.00, P ¼ 0.05) for pooled patients. Therefore, it is possible that the number of CD34 þ cells has a dose-response relationship with OS and AFS. These result support the findings previously reported by Horie et al. 18 and Saigawa et al. 4 As all cells harvested were implanted in subjects in this study, we cannot distinguish between the effects of patient characteristics and the effects of implant quantity, but both factors could potentially influence a patient's prognosis. Kawamoto et al. 20 found that the proportion of patients who had a CD34 þ cell yield of o10 6 cells/kg was as high as 35%, and that yields were especially low in older patients with ASO. Fadini et al. 28 reported that the number of circulating CD34 þ cells in diabetic patients with peripheral arterial disease was significantly reduced (22% lower) compared with diabetic patients without peripheral arterial disease. In addition, previous studies have shown that the number and angiogenic activity of circulating CD34 þ endothelial progenitor cells decreases in patients with coronary artery disease or chronic renal failure. [29] [30] [31] In these patients, CD34
þ cells may be occupied in repairing coexisting disease in the ischemic area, or CD34 þ cell activity may be otherwise consumed, so the effective number of CD34 þ cells may be lower. In addition, the prognostic factors selected for OS and AFS were different from each other in this study. Age was a prognostic factor for OS only, and Fontaine classification was a prognostic factor for AFS only. It is reasonable to expect that survival time would decrease with advancing age, but that age would not strongly affect risk of lower limb amputation. Although it seems logical that disease severity would have a relationship with risk of lower limb amputation, interestingly, there was no significant difference in survival time between patients with Fontaine III disease and those with Fontaine IV disease.
A limitation of this study was that there was no control group against which to evaluate the efficacy of cell therapies. In addition, comparability between the treatment groups was not assured, because the treatment allocation process was not randomized. That is, even after adjusting for a history of dialysis and Fontaine classification, bias caused by potential confounding factors was possible. As the BMMNC and M-PBMNC implantation procedures were performed in entirely separate centers (that is, no center performed both procedures), we were not able to statistically adjust for heterogeneity among centers, and this heterogeneity may have confounded the results.
Conclusions
We were unable to detect any significant difference in the long-term prognoses of patients with ASO-induced nooption CLI, who were treated with M-PBMNC and BMMNC. The quantity of CD34 þ cells harvested was identified as an important prognostic factor for both therapies.
